Advertisement REGENX, AAVLife enter license deal to develop new treatments for Friedreich's Ataxia - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

REGENX, AAVLife enter license deal to develop new treatments for Friedreich’s Ataxia

US-based REGENX Biosciences has entered into an agreement with France-based AAVLife for the development and commercialization of products to treat Friedreich's ataxia (FA) using NAV technology.

As part of the deal, REGENX granted AAVLife an exclusive worldwide license, with rights to sublicense, to deliver its NAV rAAVrh10 vector via non CNS routes to treat FA in humans.

Additionally, AAVLife also secured an option to obtain a non-exclusive worldwide license to additional NAV vectors for CNS delivery to treat FA.

In exchange, REGENX will receive payments in the form of up-front and on-going fees, certain milestone fees and royalties on net sales of products incorporating NAV vectors.

Furthermore, REGENX is also eligible to receive a share of any sublicensing revenues.

REGENX president and CEO Ken Mills said the company has been engaged with the team at AAVLife, including its stakeholders like the Friedreich’s Ataxia Research Alliance (FARA), since first becoming aware of their gene therapy research results and during the company’s process of formation.

"We are pleased to formally continue our collaboration with a team who has the leadership, expertise, resources, and commitment to patients that is required in order to develop innovative treatments for patients with FA through the application of NAV technology," Mills said.

"We believe this license agreement will be a key component to the successful development of treatments for patients suffering with FA."

AAVLife chief executive officer and a co-founder Amber Salzman said, "The right to the REGENX vector is a critical part of our program to advance into clinical trials a gene-therapy approach to treating Friedreich’s ataxia."